AstraZeneca signs AI drug discovery deal with insitro worth up to $1.86 billion

AstraZeneca has signed a drug discovery collaboration with insitro, the AI-driven biotech, in a deal Bloomberg reported is worth up to $1.86 billion. The goal is to find new biological targets for two notoriously stubborn disease areas. One is a liver condition most people have never heard of. The other involves the heart muscle itself. What AstraZeneca is actually paying for The partnership, announced on October 15, 2026, focuses on metabolic dysfunction-associated steatohepatitis, or MASH. That is the clinical name for an advanced form of fatty liver disease. The second focus is cardiomyopathies, a group of disorders that affect the heart muscle. Under the announced terms, AstraZeneca will make an initial payment of $40 million to insitro. On top of that, insitro could collect approximately $1.46 billion tied to discovery, development, and commercial milestones. insitro would also receive single-digit royalties on global sales of any resulting products. AstraZeneca keeps exclusive worldwide rights to the intellectual property that comes out of the work. Once insitro’s platform identifies targets, AstraZeneca takes over clinical development and handles regulatory activities. Inves...